ArticleCardio-oncology (London, England)2022
Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences.
Article in Cardio-oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 11 citations in OpenAlex.
- Co-Design and Pilot Testing of a Nurse-Led GP-Supported Self-Management Intervention for Breast Cancer Survivors with Cardiovascular Diseases: A Study Protocol.Nursing reports (Pavia, Italy) · 2026Article
- Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Current Cardio-Oncology Landscape Across Australia.Current treatment options in oncology · 2026Review
- Long-term cancer survivor awareness and learning preferences for cardio- oncologic risks: A qualitative study.Research square · 2026Article
- Integrated Cardio-oncology Service.Cardiac failure review · 2026Review
- The Cardio-Oncology Patients-What They Know and What They Should Know.Current oncology (Toronto, Ont.) · 2025Article
- Interdisciplinary Management of Cardiotoxicity in Outpatient Settings: A Survey on Practices, Perceptions and Potential for Improvement.European cardiology · 2025Article
- Cardiotoxicity in people undergoing cancer treatment - the role of the oncology nurse.Asia-Pacific journal of oncology nursing · 2024Review
- The Role of Nursing in the Delivery of Cardio-Oncology.Current treatment options in oncology · 2024Article
- Chemotherapy-related cardiotoxicity and its symptoms in patients with breast cancer: a scoping review.Systematic reviews · 2024Article
- Cardiology and oncology: a meeting of giants.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Risk and Management of Patients with Cancer and Heart Disease.Cardiology and therapy · 2023Review
- Patient Information Resources on Cardiovascular Health After Cancer Treatment: An Audit of Australian Resources.JCO global oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDedicated cardio-oncology services are emerging rapidly around the world in order to provide cardiovascular care (CV) for cancer patients. The perspectives of patients regarding their experience of cardiac surveillance during their cancer journey has not been qualitatively evaluated.
methodsAn interpretative qualitative study. Fifteen, in-depth qualitative interviews were conducted with a diverse range of community dwelling patients who attended a newly established cardio-oncology clinic in a large regional city in Australia. Data were analysed using an inductive thematic approach.
resultsKey themes were identified: (1) Access to a cardio-oncology clinic promotes information and understanding, (2) The experience of early CV intervention, (3) Factors promoting integrated care, (4) Balancing cancer treatment and CV symptoms and (5) Managing past and emerging CV risk factors.
conclusionAs cardio oncology clinics continue to emerge, this study confirms the benefit of early access to a cardiologist for management of existing or emerging CV risk factors and diseases in the context of cancer treatment. Participants valued the opportunity for regular monitoring and management of CV issues that enabled them to continue cancer treatment. However, we identified gaps in education and support towards making positive lifestyle changes that reduce the risk of CV diseases in cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.